Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 10/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8975490 | 0.90 | PRMT1 (0.52) | PRMT1NQO2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8973453 | 0.88 | PRMT1 (0.51) | PRMT1NQO2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8975727 | 0.85 | RXFP1 (0.44) | PRMT1NQO2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14369768 | 0.85 | PRMT1 (0.39) | PRMT1NQO2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12572427 | 0.83 | WDR5 (0.46) | PRMT1NQO2WDR5 | |
| SCHEMBL8975609 | 0.81 | RXFP1 (0.49) | PRMT1NQO2NPC1RXFP1WDR5 | |
| SCHEMBL2013410 | 0.81 | WDR5 (0.54) | PRMT1NQO2WDR5 | |
| SCHEMBL14369783 | 0.80 | WDR5 (0.47) | PRMT1NQO2NPC1RXFP1WDR5 | |
| SCHEMBL8975569 | 0.80 | PRMT1 (0.63) | PRMT1NQO2NPC1RXFP1WDR5 | |
| SCHEMBL8975918 | 0.79 | PRMT1 (0.41) | PRMT1NQO2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188121-B2 | Substituted pyridines as antiparasitic AZA teraryl compounds | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110257199-A1 | NOVEL TERARYL COMPOUNDS AS ANTIPARASITIC AGENTS | TIDWELL RICHARD R | 2011-10-20 | — | — | US | disclosed |
| US-20070232621-A1 | Linear dicationic terphenyls and their aza analogues as antiparasitic agents | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232621-A1 | Linear dicationic terphenyls and their aza analogues as antiparasitic agents | TPMT, TYMS, DDT | PRMT1 2351/4885NQO2 2112/4885NPC1 1749/4885 |
| US-20110257199-A1 | NOVEL TERARYL COMPOUNDS AS ANTIPARASITIC AGENTS | DDT, ZC3HAV1, MAVS | PRMT1 2522/4885NQO2 2186/4885NPC1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.